Crenolanib Treatment for FLT3-Mutated AML Blast Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FLT3 inhibitors fail to effectively deplete both peripheral blood and bone marrow blasts in FLT3 mutated acute myeloid leukemia (AML) patients, leading to short-lived clinical responses and poor prognosis, particularly in patients with additional driver mutations.
Innovation Solution
Administering Crenolanib, a selective FLT3 inhibitor, to patients with FLT3 mutated leukemia, especially those with FLT3-ITD or FLT3-TKD mutations and additional driver mutations in nuclear transport proteins like NPM1 or NUP98, to target both circulating and bone marrow blasts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current FLT3 inhibitors are administered to FLT3 mutated AML patients, then FLT3 kinase activity is inhibited, but both peripheral blood and bone marrow blasts are not effectively depleted leading to short-lived clinical responses
Solution Approach 1:
The patent introduces Crenolanib, a next-generation FLT3 inhibitor with improved molecular parameters including enhanced binding affinity to FLT3 kinase and optimized pharmacokinetic properties. These parameter changes enable the drug to achieve both potent FLT3 inhibition and effective depletion of both peripheral blood and bone marrow blasts, resolving the contradiction between clinical response duration and blast depletion efficacy
Solution Approach 2:
Crenolanib acts as an intermediary agent that bridges the gap between FLT3 kinase inhibition and comprehensive blast depletion. The drug molecules selectively bind to FLT3 kinase in both peripheral blood and bone marrow compartments, mediating the transfer of therapeutic effect from the target kinase to the leukemic blasts, thereby achieving sustained clinical responses through effective blast clearance
2Adaptability or versatility
If Crenolanib is administered to patients with FLT3 mutations and additional driver mutations in nuclear transport proteins, then selective inhibition of FLT3 is achieved, but the complexity of identifying and treating this specific patient subgroup increases
Solution Approach 1:
The patent applies local quality by tailoring the treatment approach to specific patient subgroups based on their genetic characteristics. Crenolanib is specifically indicated for patients with FLT3 mutations (ITD or TKD), with enhanced efficacy observed in those with additional driver mutations in nuclear transport proteins like NPM1 or NUP98. This localized treatment strategy optimizes therapeutic benefit for the target population while managing the complexity of patient selection through defined genetic criteria
Data Source
AI summary
The present invention includes methods for treating a FLT3 mutated proliferative disorder comprising: measuring expression of a mutated FLT3 and a one or more driver mutations in a nuclear transport protein that results in a loss of localization of the nuclear transport protein in a sample obtained from a tumor sample obtained from the patient, wherein the presence of the one or more genetic abnormalities indicates that the patient has a poor prognosis; and administering to the patient a therapeutically effective amount of Crenolanib or a pharmaceutically acceptable salt thereof, wherein the Crenolanib increases a chance of survival of the patient having both the mutated FLT3 and mutation in NPM1 or NUP98, wherein the Crenolanib, as shown below, is administered to a subject suffering from said disorder: